Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
…, H Zhou, JP Dean, PA Te Boekhorst… - The Lancet …, 2017 - thelancet.com
Background Available therapies for myelofibrosis can exacerbate cytopenias and are not
indicated for patients with severe thrombocytopenia. Pacritinib, which inhibits both JAK2 and …
indicated for patients with severe thrombocytopenia. Pacritinib, which inhibits both JAK2 and …
Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv (16)(p13q22) exhibits a specific immunophenotype with CD2 expression
HJ Adriaansen, PA Te Boekhorst, AM Hagemeijer… - 1993 - ashpublications.org
Extensive immunologic marker analysis was performed to characterize the various leukemic
cell populations in eight patients with inv(16)(p13q22) in association with acute myeloid …
cell populations in eight patients with inv(16)(p13q22) in association with acute myeloid …
Incidence of alloantibody formation after ABO‐D or extended matched red blood cell transfusions: a randomized trial (MATCH study)
…, F Hudig, PA Te Boekhorst… - …, 2016 - Wiley Online Library
BACKGROUND Most incidentally transfused patients receive only ABO‐D–compatible
transfusions and antibodies are formed in up to 8%. The effect of extended (c, C, E, K, Fy a , Jk a , …
transfusions and antibodies are formed in up to 8%. The effect of extended (c, C, E, K, Fy a , Jk a , …
Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells
PA Te Boekhorst, K de Leeuw, M Schoester, S Wittebol… - 1993 - ashpublications.org
The expression of the MDR-1-encoded P-170 glycoprotein (P-170) associated with clinical
multidrug resistance (MDR) was investigated in 52 consecutive patients with untreated acute …
multidrug resistance (MDR) was investigated in 52 consecutive patients with untreated acute …
[HTML][HTML] Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International …
…, S Slot, S Zweegman, PA Te Boekhorst… - …, 2017 - ncbi.nlm.nih.gov
The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia
and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening …
and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening …
Hyperimmune globulin for severely immunocompromised patients hospitalized with coronavirus disease 2019: a randomized, controlled trial
…, A Goorhuis, AP Kater, PA Te Boekhorst… - The Journal of …, 2023 - academic.oup.com
… Peter AW te Boekhorst , Peter AW te Boekhorst … Sammy Huygens, Quincy Hofsink, Inger S
Nijhof, Abraham Goorhuis, Arnon P Kater, Peter AW te Boekhorst, Francis Swaneveld, Věra MJ …
Nijhof, Abraham Goorhuis, Arnon P Kater, Peter AW te Boekhorst, Francis Swaneveld, Věra MJ …
A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis
…, ZH Flach, PA Te Boekhorst… - American journal …, 2007 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: In multiple sclerosis (MS), autologous hematopoietic stem
cell transplantation (AHSCT) induces a profound suppression of clinical activity and MR …
cell transplantation (AHSCT) induces a profound suppression of clinical activity and MR …
Multiple-organ failure: generalized autodestructive inflammation?
RJA Goris, TPA te Boekhorst, JKS Nuytinck… - Archives of …, 1985 - jamanetwork.com
• As multiple-organ failure (MOF) has been generally associated with sepsis, the importance
of bacterial sepsis was evaluated retrospectively in 55 trauma and 37 intra-abdominal—…
of bacterial sepsis was evaluated retrospectively in 55 trauma and 37 intra-abdominal—…
Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
PA Te Boekhorst, B Löwenberg, J Van Kapel, K Nooter… - Leukemia, 1995 - europepmc.org
High spontaneous proliferation of acute myeloid leukemia (AML) in vitro is an unfavorable,
tumor-specific prognostic factor. We investigated the frequency of drug-resistant tumor cells …
tumor-specific prognostic factor. We investigated the frequency of drug-resistant tumor cells …
[HTML][HTML] Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients
JJ Zwaginga, B van der Holt, PA Te Boekhorst… - …, 2015 - ncbi.nlm.nih.gov
… te Boekhorst, 4 Bart J. Biemond, 3 Mark-David Levin, 5 René van der Griend, 8 Anneke
Brand, 1 Sonja Zweegman, 7 Hans FM Pruijt, 9 Vera MJ Novotny, 12 Art Vreugdenhil, 6 …
Brand, 1 Sonja Zweegman, 7 Hans FM Pruijt, 9 Vera MJ Novotny, 12 Art Vreugdenhil, 6 …